Well, my list of S-Chips has just grown to 4 - GMG Global, C&O, China Animal Healthcare and now Biosensors. In brief, the group that was involved in buying a significant stake in the stent-maker, has recently brought its own people to the board. Keep a look out of things over the next 1-2 years. If things do work out, that is, the new board can wholly control JWMS, there is a potential for upside in excess of the market. Nonetheless, at this point in time, it is still too highly valued for investors looking for gains in excess of the market, within the next three months.
Edited in bold
Edited in bold
BioMatrix approval update
ReplyDelete– Regulatory standards in China continue to become more complex
– Biosensors has filed everything necessary for approval
What they didn't tell it .. approval is given only to S-Chip. LOL
So probably it is wise to change to S-Chip
i fully agree with your observation... if it does not turn red, very unlikely it can gain entry in China... as it is, all the so called "ang mo" are no longer with the company... tricky to do business in china definitely
ReplyDeleteHi, what are your take on biosensor now? seems to be dropping...
ReplyDeleteSorry for late reply. It has conducted a placement and the price has rebounded to about 1.07.
ReplyDeleteI think upside for the next 3 months will be 20 percent. Check back in May. This is a growth stock through and through so hit and run is what i will advocate at current valuations.